tradingkey.logo

Novo Nordisk A/S

NVO
View Detailed Chart

62.550USD

-4.590-6.84%
Close 04/04, 16:00ETQuotes delayed by 15 min
210.54BMarket Cap
14.37P/E TTM

Novo Nordisk A/S

62.550

-4.590-6.84%
Intraday
1m
30m
1h
D
W
M
D

Today

-6.84%

5 Days

-9.72%

1 Month

-28.95%

6 Months

-45.66%

Year to Date

-27.28%

1 Year

-50.30%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 15 analysts
BUY
Current Rating
107.836
Target Price
72.40%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

150
Total
5
Median
7
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
15
Biogen Inc
BIIB
37
Amgen Inc
AMGN
33
Alnylam Pharmaceuticals Inc
ALNY
33
Gilead Sciences Inc
GILD
30
BioMarin Pharmaceutical Inc
BMRN
29
1
2
3
...
30

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(10)
Neutral(0)
Buy(0)
Indicators
Sell(4)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.873
Sell
RSI(14)
21.550
Sell
STOCH(KDJ)(9,3,3)
4.089
Oversold
ATR(14)
2.283
Low Volatility
CCI(14)
-134.220
Sell
Williams %R
99.233
Oversold
TRIX(12,20)
-0.867
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
67.066
Sell
MA10
69.542
Sell
MA20
73.804
Sell
MA50
81.055
Sell
MA100
89.250
Sell
MA200
109.107
Sell

Company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company codeNVO
CompanyNovo Nordisk A/S
CEOMr. Lars Fruergaard Joergensen
Websitehttps://www.novonordisk.com/
tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.